Prognostic and therapeutic implications of minimal residual disease at the time of transplantation in acute leukemia (Q38028808)

27 August 2017

title

Prognostic and therapeutic implications of minimal residual disease at the time of transplantation in acute leukemia (English)

1 reference

27 August 2017

author

Frederick R. Appelbaum

series ordinal

2

object named as

F R Appelbaum

1 reference

27 August 2017

S A Buckley

1

1 reference

27 August 2017

R B Walter

series ordinal

3

1 reference

27 August 2017

language of work or name

English

0 references

publication date

23 July 2012

1 reference

Bone Marrow Transplantation

27 August 2017

published in

1 reference

27 August 2017

volume

48

1 reference

27 August 2017

issue

5

1 reference

27 August 2017

page(s)

630-641

1 reference

https://scigraph.springernature.com/pub.10.1038/bmt.2012.139

27 August 2017

exact match

0 references

cites work

Acute myeloid leukaemia

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2012.139

Acute lymphoblastic leukaemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2012.139

Minimal residual disease in leukaemia patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2012.139

Determination of minimal residual disease in leukaemia patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2012.139

Role of minimal residual disease monitoring in adult and pediatric acute lymphoblastic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2012.139

Progress of minimal residual disease studies in childhood acute leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2012.139

Towards individualized follow-up in adult acute myeloid leukemia in remission

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2012.139

Acute lymphoblastic leukemia: monitoring minimal residual disease as a therapeutic principle

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2012.139

Prognostic and therapeutic implications of minimal residual disease detection in acute myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2012.139

Minimal residual disease monitoring in childhood acute lymphoblastic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2012.139

NCI First International Workshop on the Biology, Prevention, and Treatment of Relapse after Allogeneic Hematopoietic Stem Cell Transplantation: report from the Committee on Disease-Specific Methods and Strategies for Monitoring Relapse following All

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2012.139

Minimal residual disease following allogeneic hematopoietic stem cell transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2012.139

Practical application of minimal residual disease assessment in childhood acute lymphoblastic leukaemia annotation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2012.139

Minimal residual disease markers before and after allogeneic hematopoietic stem cell transplantation in acute myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2012.139

Prognostic impact of discordant results from cytogenetics and flow cytometry in patients with acute myeloid leukemia undergoing hematopoietic cell transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2012.139

Extensive Histological and Cytological Survey of Patients with Acute Leukaemia in "Complete Remission"

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2012.139

Allogeneic hematopoietic cell transplantation with full-intensity conditioning for adult acute lymphoblastic leukemia: results from a single center, 1998-2006

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2012.139

Accurate quantitation of residual tumor burden at bone marrow harvest predicts timing of subsequent relapse in patients with common ALL treated by autologous bone marrow transplantation. Nagoya BMT Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2012.139

Outcome of treatment in adults with Philadelphia chromosome-positive acute lymphoblastic leukemia--results of the prospective multicenter LALA-94 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2012.139

Minimal residual disease (MRD) status prior to allogeneic stem cell transplantation is a powerful predictor for post-transplant outcome in children with ALL.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2012.139

Detectable minimal residual disease before allogeneic hematopoietic stem cell transplantation predicts extremely poor prognosis in children with acute lymphoblastic leukemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2012.139

Minimal residual disease is an important predictive factor of outcome in children with relapsed 'high-risk' acute lymphoblastic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2012.139

Prognostic value of minimal residual disease quantification before allogeneic stem-cell transplantation in relapsed childhood acute lymphoblastic leukemia: the ALL-REZ BFM Study Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2012.139

Relationship between minimal residual disease measured by multiparametric flow cytometry prior to allogeneic hematopoietic stem cell transplantation and outcome in children with acute lymphoblastic leukemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2012.139

Minimal residual disease is a significant predictor of treatment failure in non T-lineage adult acute lymphoblastic leukaemia: final results of the international trial UKALL XII/ECOG2993.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2012.139

High success rate of hematopoietic cell transplantation regardless of donor source in children with very high-risk leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2012.139

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2012.139

Pretransplant minimal residual disease level predicts clinical outcome in patients with acute myeloid leukemia receiving high-dose chemotherapy and autologous stem cell transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2012.139

Toward optimization of postremission therapy for residual disease-positive patients with acute myeloid leukemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2012.139

High WT1 gene expression before haematopoietic stem cell transplant in children with acute myeloid leukaemia predicts poor event-free survival

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2012.139

Impact of pretransplantation minimal residual disease, as detected by multiparametric flow cytometry, on outcome of myeloablative hematopoietic cell transplantation for acute myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2012.139

Nonmyeloablative allogeneic hematopoietic cell transplantation in patients with acute myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2012.139

Non-myeloablative conditioning with allogeneic hematopoietic cell transplantation for the treatment of high-risk acute lymphoblastic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2012.139

Increasing mixed chimerism is an important prognostic factor for unfavorable outcome in children with acute lymphoblastic leukemia after allogeneic stem-cell transplantation: possible role for pre-emptive immunotherapy?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2012.139

Monitoring of post-transplant remission of childhood malignancies: is there a standard?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2012.139

Minimal residual disease diagnostics in myeloid malignancies in the post transplant period

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2012.139

Monitoring of minimal residual disease by quantitative WT1 gene expression following reduced intensity conditioning allogeneic stem cell transplantation in acute myeloid leukemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2012.139

Clinical significance of minimal residual disease detected by multidimensional flow cytometry: serial monitoring after allogeneic stem cell transplantation for acute leukemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2012.139

Prospective minimal residual disease monitoring to predict relapse of acute promyelocytic leukemia and to direct pre-emptive arsenic trioxide therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2012.139

Improved risk classification for risk-specific therapy based on the molecular study of minimal residual disease (MRD) in adult acute lymphoblastic leukemia (ALL).

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2012.139

Minimal residual disease-directed therapy for childhood acute myeloid leukaemia: results of the AML02 multicentre trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2012.139

Association of Human Development Index with rates and outcomes of hematopoietic stem cell transplantation for patients with acute leukemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2012.139

Minimal residual disease-based role of imatinib as a first-line interim therapy prior to allogeneic stem cell transplantation in Philadelphia chromosome-positive acute lymphoblastic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2012.139

Targeted therapy with the T-cell-engaging antibody blinatumomab of chemotherapy-refractory minimal residual disease in B-lineage acute lymphoblastic leukemia patients results in high response rate and prolonged leukemia-free survival.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2012.139

Successful donor leukocyte transfusion at molecular relapse for a patient with acute myeloid leukemia who was treated with allogenic bone marrow transplantation: importance of the monitoring of minimal residual disease by WT1 assay.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2012.139

Preemptive immunotherapy in childhood acute myeloid leukemia for patients showing evidence of mixed chimerism after allogeneic stem cell transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2012.139

Risk stratification-directed donor lymphocyte infusion could reduce relapse of standard-risk acute leukemia patients after allogeneic hematopoietic stem cell transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2012.139

Monitoring of donor chimerism in sorted CD34+ peripheral blood cells allows the sensitive detection of imminent relapse after allogeneic stem cell transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2012.139

Azacitidine for treatment of imminent relapse in MDS or AML patients after allogeneic HSCT: results of the RELAZA trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2012.139

Early molecular response to posttransplantation imatinib determines outcome in MRD+ Philadelphia-positive acute lymphoblastic leukemia (Ph+ ALL).

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2012.139

High-throughput sequencing detects minimal residual disease in acute T lymphoblastic leukemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2012.139

Standardized MRD quantification in European ALL trials: proceedings of the Second International Symposium on MRD assessment in Kiel, Germany, 18-20 September 2008.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2012.139

Impact of disease burden at time of allogeneic stem cell transplantation in adults with acute myeloid leukemia and myelodysplastic syndromes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2012.139

Detection of minimal residual disease in acute myelogenous leukemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2012.139

7 January 2021

Monitoring of minimal residual disease in acute myeloid leukemia

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2012.139

7 January 2021

An update from the International Bone Marrow Transplant Registry and the Autologous Blood and Marrow Transplant Registry on current activity in hematopoietic stem cell transplantation.

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2012.139

7 January 2021

Pretransplantation burden of leukemic progenitor cells as a predictor of relapse after bone marrow transplantation for acute lymphoblastic leukemia

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2012.139

7 January 2021

Real-time quantitative PCR for detection of minimal residual disease before allogeneic stem cell transplantation predicts outcome in children with acute lymphoblastic leukemia

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2012.139

7 January 2021

The significance of graft-versus-host disease and pretransplantation minimal residual disease status to outcome after allogeneic stem cell transplantation in patients with acute lymphoblastic leukemia

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2012.139

7 January 2021

Minimal residual disease tests provide an independent predictor of clinical outcome in adult acute lymphoblastic leukemia

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2012.139

7 January 2021

Allogeneic bone marrow transplantation (BMT) for adults with acute lymphoblastic leukemia (ALL): predictive role of minimal residual disease monitoring on relapse

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2012.139

7 January 2021

Clinical value of immunological monitoring of minimal residual disease in acute lymphoblastic leukaemia after allogeneic transplantation

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2012.139

7 January 2021

Level of minimal residual disease prior to haematopoietic stem cell transplantation predicts prognosis in paediatric patients with acute lymphoblastic leukaemia: a report of the Pre-BMT MRD Study Group

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2012.139

7 January 2021

Predictors of relapse and overall survival in Philadelphia chromosome-positive acute lymphoblastic leukemia after transplantation

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2012.139

7 January 2021

Clearance of minimal residual disease after allogeneic stem cell transplantation and the prediction of the clinical outcome of adult patients with high-risk acute lymphoblastic leukemia

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2012.139

7 January 2021

Status of minimal residual disease determines outcome of autologous hematopoietic SCT in adult ALL

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2012.139

7 January 2021

Detectable minimal residual disease before hematopoietic cell transplantation is prognostic but does not preclude cure for children with very-high-risk leukemia

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2012.139

7 January 2021

Impact of pretransplant minimal residual disease after cord blood transplantation for childhood acute lymphoblastic leukemia in remission: an Eurocord, PDWP–EBMT analysis

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2012.139

7 January 2021

Transplant characteristics: minimal residual disease and impaired megakaryocytic colony growth as sensitive parameters for predicting relapse in acute myeloid leukemia

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2012.139

7 January 2021

Elevated levels of WT1 transcripts in bone marrow harvests are associated with a high relapse risk in patients autografted for acute myeloid leukaemia

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2012.139

7 January 2021

The kinetics of reduction of minimal residual disease impacts on duration of response and survival of patients with acute myeloid leukemia

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2012.139

7 January 2021

Minimal residula disease status as a predictor of relapse after allogenic bone marrow transplantation for children with acute lymphoblastic leukaemia

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2012.139

7 January 2021

Outcome of patients with acute promyelocytic leukemia failing to front-line treatment with all-trans retinoic acid and anthracycline-based chemotherapy (PETHEMA protocols LPA96 and LPA99): benefit of an early intervention

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2012.139

7 January 2021

Graft-versus-leukemia effect in acute lymphoblastic leukemia: the importance of tumor burden and early detection

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2012.139

7 January 2021

Donor lymphocyte infusions for the treatment of minimal residual disease in acute leukemia

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2012.139

7 January 2021

Evaluation of immunomodulatory treatment based on conventional and lineage-specific chimerism analysis in patients with myeloid malignancies after myeloablative allogeneic hematopoietic cell transplantation

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2012.139

7 January 2021

Preemptive alloimmune intervention in high-risk pediatric acute lymphoblastic leukemia patients guided by minimal residual disease level before stem cell transplantation

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2012.139

7 January 2021

Salvage of patients with acute promyelocytic leukaemia with residual disease following ABMT performed in second CR using all-trans retinoic acid

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2012.139

7 January 2021

The GTPase-activating protein ARAP3 regulates chemotaxis and adhesion-dependent processes in neutrophils

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2012.139

7 January 2021

Acute lymphoblastic leukemia

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2012.139

7 January 2021

Identifiers

DOI

10.1038/BMT.2012.139

1 reference

Dimensions Publication ID

27 August 2017

1032048134

0 references

1 reference